Brookline Capital Management Comments on Unicycive Therapeutics, Inc.’s Q2 2024 Earnings (NASDAQ:UNCY)

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) – Investment analysts at Brookline Capital Management issued their Q2 2024 earnings per share (EPS) estimates for Unicycive Therapeutics in a research report issued to clients and investors on Tuesday, July 9th. Brookline Capital Management analyst K. Raja anticipates that the company will post earnings per share of ($0.25) for the quarter. Brookline Capital Management has a “Strong-Buy” rating on the stock. The consensus estimate for Unicycive Therapeutics’ current full-year earnings is ($0.82) per share. Brookline Capital Management also issued estimates for Unicycive Therapeutics’ Q3 2024 earnings at ($0.26) EPS, Q4 2024 earnings at ($0.26) EPS, FY2024 earnings at ($1.00) EPS, FY2025 earnings at ($0.23) EPS, FY2026 earnings at $1.81 EPS, FY2027 earnings at $2.52 EPS and FY2028 earnings at $1.33 EPS.

Unicycive Therapeutics (NASDAQ:UNCY) last issued its quarterly earnings data on Monday, May 13th. The company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.09).

Several other research firms have also recently commented on UNCY. Benchmark reiterated a “speculative buy” rating and issued a $3.00 price target on shares of Unicycive Therapeutics in a research note on Friday, May 31st. HC Wainwright reiterated a “buy” rating and issued a $4.50 price target on shares of Unicycive Therapeutics in a research note on Wednesday. Finally, Piper Sandler began coverage on Unicycive Therapeutics in a research note on Thursday, April 4th. They issued an “overweight” rating and a $9.00 price target on the stock. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $5.63.

Unicycive Therapeutics Trading Down 1.2 %

NASDAQ:UNCY opened at $0.48 on Friday. Unicycive Therapeutics has a one year low of $0.34 and a one year high of $1.82. The business’s 50-day simple moving average is $0.78 and its 200 day simple moving average is $1.04.

Institutional Trading of Unicycive Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Virtu Financial LLC bought a new stake in Unicycive Therapeutics in the first quarter valued at about $36,000. Rosalind Advisors Inc. bought a new position in shares of Unicycive Therapeutics during the first quarter valued at approximately $2,594,000. Finally, BVF Inc. IL grew its holdings in shares of Unicycive Therapeutics by 70.5% during the first quarter. BVF Inc. IL now owns 3,611,601 shares of the company’s stock valued at $4,984,000 after purchasing an additional 1,493,462 shares during the last quarter. 40.42% of the stock is owned by institutional investors.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.